Filing Details

Accession Number:
0001140361-11-054301
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-18 13:55:46
Reporting Period:
2011-11-17
Filing Date:
2011-11-18
Accepted Time:
2011-11-18 13:55:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-17 20,000 $12.60 327,697 No 4 M Direct
Common Stock Disposition 2011-11-17 1,400 $72.76 326,297 No 4 S Direct
Common Stock Disposition 2011-11-17 6,400 $73.79 319,897 No 4 S Direct
Common Stock Disposition 2011-11-17 1,200 $74.91 318,697 No 4 S Direct
Common Stock Disposition 2011-11-17 4,900 $75.94 313,797 No 4 S Direct
Common Stock Disposition 2011-11-17 1,100 $76.66 312,697 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-11-17 20,000 $0.00 20,000 $12.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,320 2012-01-28 No 4 M Direct
Footnotes
  1. The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.
  2. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.27 to $73.21, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6 to this Form 4.
  3. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $73.41 to $74.3875, inclusive.
  4. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $74.41 to $75.37, inclusive.
  5. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $75.494 to $76.4525, inclusive.
  6. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $76.50 to $76.82, inclusive.
  7. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.